80 results
Page 3 of 4
8-K
EX-1.1
5pfx6m1ht7cnwn
19 Feb 21
Y-mAbs Announces Proposed Public Offering of Common Stock
6:01am
8-K
1ehshz zceh
19 Feb 21
Y-mAbs Announces Proposed Public Offering of Common Stock
6:01am
424B5
nb61orgt4hys7
18 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
3irttq rwey95c63
17 Feb 21
Prospectus supplement for primary offering
6:02am
8-K
EX-99.1
d6rjn4udjzfs 02
28 Dec 20
Y-mAbs Announces Sale of Priority Review Voucher
1:20pm
8-K
EX-10.1
jrmsrb
22 Dec 20
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-99.1
bh5mp3ln y8479t89s
18 Dec 20
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China
10:38am
8-K
EX-99.1
52wac ho6
18 Dec 20
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe
10:36am
8-K
EX-99.1
30a3ecfaglfzb
16 Dec 20
Y-mAbs Announces Pipeline Update
9:15am
8-K
EX-99.1
71o9sg373q7 wc554vzt
9 Dec 20
Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO
4:15pm
8-K
EX-99.1
9dr6z zcv50hice
4 Dec 20
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
9:09am
8-K
EX-99.1
q8w505ahuhjbekkn
25 Nov 20
FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma
5:29pm
8-K
EX-99.1
z3oujx2 70mv
26 Oct 20
Y-mAbs Announces FDA Clearance of IND for Lutetium- 177 Labeled Omburtamab Antibody for Adult Indications
9:48am
8-K
EX-99.1
ze8j9yjknqhnqeb7
14 Oct 20
Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody
9:06am
8-K
EX-99.1
6oxvg
6 Aug 20
Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA
11:27am
8-K
EX-99.1
xsc72oqpl 9k
30 Jun 20
Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA
4:27pm